Alejandro Olivé
A5048645990- Systemic Lupus Erythematosus Research
- Salivary Gland Disorders and Functions
- Systemic Sclerosis and Related Diseases
- Vasculitis and related conditions
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Ocular Diseases and Behçet’s Syndrome
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Otitis Media and Relapsing Polychondritis
- Lymphoma Diagnosis and Treatment
- Sarcoidosis and Beryllium Toxicity Research
- Musculoskeletal Disorders and Rehabilitation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Healthcare Systems and Technology
- Urticaria and Related Conditions
- Retinal and Optic Conditions
- Inflammatory Myopathies and Dermatomyositis
- Renal Diseases and Glomerulopathies
- Oral Health Pathology and Treatment
- IgG4-Related and Inflammatory Diseases
- Infectious Diseases and Tuberculosis
- Atherosclerosis and Cardiovascular Diseases
- Orthopedic Infections and Treatments
- Immune Cell Function and Interaction
- Eosinophilic Disorders and Syndromes
Hospital Universitari Germans Trias i Pujol
2016-2025
Universitat Autònoma de Barcelona
1999-2020
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2015-2020
Hospital Municipal de Badalona
2003-2019
Center for Rheumatology
2001-2018
Trias (Greece)
2017
Instituto de Investigación Biosanitaria de Granada
2014-2016
University Hospital Complex Of Vigo
2016
Universidad de Málaga
2016
Ayuntamiento de Bilbao
2016
Summary Intravenous heparin followed by oral anticoagulant therapy (e. g. with coumarin) is still the most widely used treatment for deep venous thromboembolism. Self-administered subcutaneous injections of have been thought as a promising alternative to coumarin, but high doses required ongoing prophylaxis raised concerns about possible development bone disease. Certainly, long-term has reported cause osteoporosis in both laboratory animals and humans. This study aimed compare efficacy...
Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and small series of patients with AOSD. The aim this multicenter study was assess the TCZ AOSD conventional treatment.This a retrospective open-label treatment 34 who had experienced an inadequate response corticosteroids at least 1 synthetic immunosuppressive drug also, many cases, biologic agents.The mean ± SD age (8 men 26 women) 38.7 16.1 years....
Objective. The aim of this study was to assess the efficacy anti-TNF-α therapy in refractory uveitis due Behçet's disease (BD). Methods. We performed a multicentre 124 patients with BD conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. Patients were treated for 12 months infliximab (IFX) (3–5 mg/kg 0, 2 6 weeks then every 4–8 weeks) or adalimumab (ADA) (usually 40 mg weeks). main outcome measures degree anterior posterior chamber...
Objective: This study aimed to investigate the effectiveness and safety of single repeated courses rituximab in patients with refractory lupus. Methods: LESIMAB is a multicenter, retrospective, longitudinal lupus who have not responded standard therapy been treated rituximab. Response rates at six months follow-up were defined as efficacy outcomes. Complete response was SELENA-SLEDAI score ≤ two Flare Index zero. Partial reduction ≥four points no new or worsening symptoms. Adverse events...
Adult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the ANK a AOSD patients. Multicenter retrospective open-label study. was used due lack synthetic immunosuppressive drugs some also at least 1 biologic agent. Forty-one patients (26 women/15 men) were recruited. They had mean age 34.4 ± 14 years median [interquartile range (IQR)]...
Objective To compare the efficacy of infliximab ( IFX ) versus adalimumab ADA as a first‐line biologic drug over 1 year treatment in large series patients with refractory uveitis due to Behçet's disease BD ). Methods We conducted an open‐label multicenter study for ‐related conventional nonbiologic treatment. or was chosen agent based on physician and patient agreement. Patients received 3–5 mg/kg intravenous at 0, 2, 6 weeks every 4–8 thereafter, 40 mg subcutaneous other week without...
Abstract Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was an observational, multicentre study RA-ILD treated at least one dose ABA. ILD diagnosed by high-resolution CT (HRCT). We analysed following variables baseline (ABA initiation), 12 months and end follow-up: Modified Medical Research Council (MMRC) scale (1-point change), forced vital capacity (FVC) or diffusion for carbon monoxide (DLCO) (improvement...
The aim of the study was to profile those patients included in RELESSER registry with histologically proven renal involvement order better understand current state lupus nephritis (LN) Spain. RELESSER-TRANS is a multicenter cross-sectional an analytical component. Information collected from medical records systemic erythematosus who were followed at participating rheumatology units. A total 359 variables including demographic data, clinical manifestations, disease activity, severity,...
The purpose of this study was to assess the prevalence, associated factors, and impact on mortality primary respiratory disease in a large systemic lupus erythematosus (SLE) retrospective cohort.All adult patients RELESSER-TRANS (Registry Systemic Lupus Erythematosus Patients Spanish Society Rheumatology [SER], cross-sectional phase) registry were retrospectively investigated for presence pleuropulmonary manifestations.In total 3215 included. At least one manifestation present 31% patients....
Abstract Objective The aim of the present study was to describe demographic, clinical and immunological characteristics patients with late-onset (≥50 years) SLE vs early-onset (<50 years). Methods We performed a cross-sectional retrospective 3619 from RELESSER database (National Register Patients Systemic Lupus Erythematosus Spanish Society Rheumatology). Results A total 565 (15.6%) were classified as 3054 (84.4%) SLE. male-to-female ratio 5:1. Mean (s.d.) age at diagnosis in group...
To quantify the mortality risk in a large, well-characterized cohort of Sjögren's disease (SjD) patients and to identify independent predictors this population. We included 314 diagnosed with SjD according 2002 American-European Consensus Group criteria from prospective, multicenter SjögrenSER-PROS cohort. Detailed data on systemic manifestations, serological markers, activity, was collected after 9 years follow up. The primary outcome overall mortality, secondary analyses aimed using Cox...
Objectives. To identify patterns (clusters) of damage manifestations within a large cohort SLE patients and evaluate the potential association these clusters with higher risk mortality. Methods. This is multicentre, descriptive, cross-sectional study 3656 from Spanish Society Rheumatology Lupus Registry. Organ was ascertained using Systemic International Collaborating Clinics Damage Index. Using cluster analysis, groups similar were identified. Then, overall compared as well subgroup every...
Objective To compare the prevalence of main comorbidities in 2 large cohorts patients with primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), a focus on cardiovascular (CV) diseases. Methods This was cross‐sectional multicenter study where more relevant compared. Patients under followup from SJOGRENSER (Spanish Rheumatology Society Registry Primary SS) RELESSER SLE), who fulfilled 2002 American–European Consensus Group 1997 American College classification criteria,...
Objective. To describe the incidence of bacteremia in a large multicentric cohort patients with systemic lupus erythematosus (SLE) and their clinical characteristics to identify risk factors. Methods. All bacteremic episodes from Spanish RELESSER registry were included. Clinical laboratory concerning SLE status, as well comorbidities at time infection, retrospectively collected. A comparison sex- age-matched controls without was made. logistic regression conducted. Results. The study...
Retrospective studies have shown antineutrophil cytoplasmic antibody (ANCA) positivity in patients treated for Graves' hyperthyroidism; ANCA has been attributed to either antithyroid drugs or the disease itself. The aim of this study was determine at diagnosis and after treatment with methimazole evaluate relationship between hyperthyroidism evolution. Thirty recently diagnosed were prospectively studied. determined by indirect immunofluorescence. autoantibodies against specific antigens...